Psychedelic Research Bulletin: October 2022 Post published:November 3, 2022 Post category:Psychedelics Research Review
Analysis: COMPASS Pathways Phase 2b Psilocybin Trial Published in NEJM Post published:November 2, 2022 Post category:Analysis
Lusaris Therapeutics Launches with $60 Million Series A Financing to Redefine the Treatment of Severe Neuropsychiatric and Neurological Disorders Post published:November 2, 2022 Post category:Press Release
atai Life Sciences to Participate in November Investor Events & Healthcare Conferences Post published:November 2, 2022 Post category:Press Release
PharmaTher Enters into Exclusive Option Agreement with Case Western Reserve University to Develop and Commercialize Ketamine for Rett Syndrome Post published:November 2, 2022 Post category:Press Release
Braxia Scientific Announces Voting Results from the Annual General and Special Meeting of Shareholders Post published:November 2, 2022 Post category:Press Release
Numinus Re-Launches “Psychedelic Therapy Frontiers” Podcast with additional hosts and topics Post published:November 1, 2022 Post category:Press Release
Apex Labs Granted Approval for North America’s First Take Home Psilocybin Clinical Trial Post published:November 1, 2022 Post category:Press Release
Reunion Neuroscience to Present at Upcoming November Conferences Post published:November 1, 2022 Post category:Press Release
Numinus to Participate in Wonderland: Miami on November 3-5, 2022 Post published:October 31, 2022 Post category:Press Release